Hyperglycemia with antipsychotic treatment

Area of Science:

• Psychiatry and Endocrinology
• Pharmacology and Public Health

Background:

• Diabetes and mental disorders are prevalent chronic conditions in the U.S.
• Atypical antipsychotics represent a significant treatment advancement for mental disorders.
• Increased use of these medications has revealed unanticipated side effects, including treatment-emergent diabetes.

Purpose of the Study:

• To examine the increased risk of type 2 diabetes in patients with mental disorders, particularly schizophrenia, treated with atypical antipsychotics.
• To understand the contributing factors to treatment-emergent diabetes in this population.

Main Methods:

• Review of existing literature on atypical antipsychotic use and diabetes incidence.
• Analysis of risk factors associated with antipsychotic medication side effects.
• Consideration of underlying genetic predispositions and lifestyle factors.

Main Results:

• Treatment-emergent diabetes is a documented side effect of both conventional and atypical antipsychotics.
• Individuals with schizophrenia exhibit a heightened risk for developing type 2 diabetes.
• Multiple factors contribute to this increased risk, including medication side effects, genetic vulnerability, and lifestyle choices.

Conclusions:

• Atypical antipsychotics, despite their benefits, pose a significant risk for inducing diabetes.
• Patients with schizophrenia are particularly vulnerable to type 2 diabetes due to a combination of medication effects, predisposition, and lifestyle.
• Further research and monitoring are crucial to mitigate this adverse effect.